JPWO2020060781A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020060781A5 JPWO2020060781A5 JP2021539334A JP2021539334A JPWO2020060781A5 JP WO2020060781 A5 JPWO2020060781 A5 JP WO2020060781A5 JP 2021539334 A JP2021539334 A JP 2021539334A JP 2021539334 A JP2021539334 A JP 2021539334A JP WO2020060781 A5 JPWO2020060781 A5 JP WO2020060781A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 claims 7
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 claims 6
- 241000282567 Macaca fascicularis Species 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000000905 Cadherin Human genes 0.000 claims 2
- 108050007957 Cadherin Proteins 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 230000006051 NK cell activation Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000006044 T cell activation Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024127876A JP2024156878A (ja) | 2018-09-17 | 2024-08-02 | 抗ｋｌｒｇ１抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732329P | 2018-09-17 | 2018-09-17 | |
| US62/732,329 | 2018-09-17 | ||
| PCT/US2019/050110 WO2020060781A1 (en) | 2018-09-17 | 2019-09-06 | Anti-klrg1 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024127876A Division JP2024156878A (ja) | 2018-09-17 | 2024-08-02 | 抗ｋｌｒｇ１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501065A JP2022501065A (ja) | 2022-01-06 |
| JPWO2020060781A5 true JPWO2020060781A5 (enExample) | 2022-09-14 |
| JP7654548B2 JP7654548B2 (ja) | 2025-04-01 |
Family
ID=69887899
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539334A Active JP7654548B2 (ja) | 2018-09-17 | 2019-09-06 | 抗ｋｌｒｇ１抗体 |
| JP2024127876A Pending JP2024156878A (ja) | 2018-09-17 | 2024-08-02 | 抗ｋｌｒｇ１抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024127876A Pending JP2024156878A (ja) | 2018-09-17 | 2024-08-02 | 抗ｋｌｒｇ１抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12365735B2 (enExample) |
| EP (1) | EP3852779A4 (enExample) |
| JP (2) | JP7654548B2 (enExample) |
| KR (1) | KR20210060477A (enExample) |
| CN (2) | CN112752580B (enExample) |
| AU (1) | AU2019344524A1 (enExample) |
| BR (1) | BR112021004553A2 (enExample) |
| CA (1) | CA3113069A1 (enExample) |
| EA (1) | EA202190647A1 (enExample) |
| IL (2) | IL281594B1 (enExample) |
| MX (2) | MX2021003119A (enExample) |
| SG (1) | SG11202102114UA (enExample) |
| WO (1) | WO2020060781A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112752580B (zh) | 2018-09-17 | 2024-12-13 | 布里格姆妇女医院 | 抗klrg1抗体 |
| WO2022056289A1 (en) * | 2020-09-11 | 2022-03-17 | National Jewish Health | Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells |
| IL307241A (en) * | 2021-03-26 | 2023-11-01 | Abcuro Inc | Antibodies against KLRG1 |
| WO2022204529A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| WO2024072872A2 (en) * | 2022-09-27 | 2024-04-04 | The Brigham And Women's Hospital, Inc. | Klrg1 signalling therapy for infectious disease |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| EP2325206B1 (en) | 2004-11-12 | 2014-03-19 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| EP1858925A2 (en) | 2005-01-12 | 2007-11-28 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| CA2947292C (en) * | 2006-12-27 | 2019-07-23 | Emory University | Compositions and methods for the treatment of infections and tumors |
| CN101952454B (zh) | 2008-02-08 | 2014-06-04 | 米迪缪尼有限公司 | 具有减弱的Fc配体亲和性的抗IFNAR1抗体 |
| ES2624835T3 (es) * | 2009-08-06 | 2017-07-17 | Immunas Pharma, Inc. | Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos |
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| SG188285A1 (en) * | 2010-09-02 | 2013-04-30 | Vaccinex Inc | Anti-cxcl13 antibodies and methods of using the same |
| HUE041335T2 (hu) | 2011-03-29 | 2019-05-28 | Roche Glycart Ag | Antitest FC-variánsok |
| KR20140059168A (ko) | 2011-04-21 | 2014-05-15 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 시신경 척수염 치료용 조성물 및 치료 방법 |
| DK3424953T3 (en) | 2011-06-06 | 2020-11-02 | Novo Nordisk As | Terapeutiske antistoffer |
| JPWO2012176765A1 (ja) | 2011-06-24 | 2015-02-23 | 株式会社ペルセウスプロテオミクス | 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体 |
| US20160068613A1 (en) | 2013-04-29 | 2016-03-10 | Hoffmann-La Roche Inc. | Fc-receptor binding modified asymmetric antibodies and methods of use |
| CN107073088A (zh) * | 2014-03-19 | 2017-08-18 | 台湾基督长老教会马偕医疗财团法人马偕纪念医院 | 免疫原性糖肽、包含所述糖肽的组合物及其用途 |
| WO2016009487A1 (ja) | 2014-07-14 | 2016-01-21 | 三菱電機株式会社 | 空気調和装置 |
| SG10202010506TA (en) | 2015-07-30 | 2020-11-27 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
| UA126278C2 (uk) | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептиди, які зв'язують cd3 |
| RU2018116402A (ru) | 2015-10-07 | 2019-11-07 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антитела, четырехвалентные в отношении костимуляторного tnf-рецептора |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| US11472877B2 (en) | 2016-03-04 | 2022-10-18 | Alector Llc | Anti-TREM1 antibodies and methods of use thereof |
| EP3471539A4 (en) | 2016-06-03 | 2020-02-26 | The Brigham and Women's Hospital | SIGNALING PROCESSING WITH KLRG1 |
| WO2018053264A2 (en) * | 2016-09-16 | 2018-03-22 | The Brigham And Women's Hospital, Inc. | Klrg1 depletion therapy |
| WO2018140831A2 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| EP3610010A4 (en) | 2017-04-14 | 2021-02-24 | Kodiak Sciences Inc. | COMPLEMENT FACTOR-D-ANTAGONIST-ANTIBODIES AND CONJUGATES THEREOF |
| CN111093702A (zh) | 2017-06-22 | 2020-05-01 | 财团法人生物技术开发中心 | 靶细胞依赖性T细胞的接合和活化型不对称异二聚Fc-ScFv融合抗体形式用于癌症治疗 |
| US20210002373A1 (en) | 2018-03-01 | 2021-01-07 | Nextcure, Inc. | KLRG1 Binding Compositions and Methods of Use Thereof |
| CN112752580B (zh) | 2018-09-17 | 2024-12-13 | 布里格姆妇女医院 | 抗klrg1抗体 |
| BR112021019128A2 (pt) | 2019-04-09 | 2022-01-04 | Abcuro Inc | Anticorpos de depleção de membro 1 da subfamília g do receptor tipo lectina de célula assassina (klrg1) |
| IL307241A (en) | 2021-03-26 | 2023-11-01 | Abcuro Inc | Antibodies against KLRG1 |
-
2019
- 2019-09-06 CN CN201980060735.4A patent/CN112752580B/zh active Active
- 2019-09-06 AU AU2019344524A patent/AU2019344524A1/en active Pending
- 2019-09-06 KR KR1020217008068A patent/KR20210060477A/ko active Pending
- 2019-09-06 US US17/285,793 patent/US12365735B2/en active Active
- 2019-09-06 IL IL281594A patent/IL281594B1/en unknown
- 2019-09-06 EA EA202190647A patent/EA202190647A1/ru unknown
- 2019-09-06 EP EP19862063.5A patent/EP3852779A4/en active Pending
- 2019-09-06 BR BR112021004553-8A patent/BR112021004553A2/pt unknown
- 2019-09-06 MX MX2021003119A patent/MX2021003119A/es unknown
- 2019-09-06 CN CN202411978380.6A patent/CN119638835A/zh active Pending
- 2019-09-06 JP JP2021539334A patent/JP7654548B2/ja active Active
- 2019-09-06 WO PCT/US2019/050110 patent/WO2020060781A1/en not_active Ceased
- 2019-09-06 CA CA3113069A patent/CA3113069A1/en active Pending
- 2019-09-06 SG SG11202102114UA patent/SG11202102114UA/en unknown
-
2021
- 2021-03-16 MX MX2025008993A patent/MX2025008993A/es unknown
-
2024
- 2024-08-02 JP JP2024127876A patent/JP2024156878A/ja active Pending
-
2025
- 2025-09-04 IL IL323170A patent/IL323170A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12024559B2 (en) | Fusions with CD8 antigen binding molecules for modulating immune cell function | |
| CA2854817C (en) | Combination therapies using anti-pseudomonas psl and pcrv binding molecules | |
| JP2020511947A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2020513791A5 (enExample) | ||
| AU2018271915B2 (en) | Therapeutic anti-CD40 ligand antibodies | |
| JP2018533371A5 (enExample) | ||
| JP2017536341A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| JP2016511277A5 (enExample) | ||
| CA3222764A1 (en) | Anti-ccr8 antibodies and uses thereof | |
| JP2018510617A5 (enExample) | ||
| IL262726B1 (en) | Antibodies recognizing tau | |
| JP2010524435A5 (enExample) | ||
| JP2012530496A5 (enExample) | ||
| CN104995209A (zh) | 使用抗假单胞菌Psl和PcrV结合分子的联合治疗 | |
| RU2013110874A (ru) | Антитела против il-18r1 и их применения | |
| JP2016503067A5 (enExample) | ||
| JP2013509158A5 (enExample) | ||
| JP2024156878A5 (enExample) | ||
| CN116390953A (zh) | 靶向人密蛋白18.2的抗体及其用途 | |
| TW201134489A (en) | Basigin binding proteins | |
| US20240010695A1 (en) | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function | |
| JPWO2018206790A5 (enExample) | ||
| CN112533945A (zh) | 优化的结合gp41的分子及其用途 |